CR20220374A - Métodos de tratamiento de la esplenomegalia - Google Patents

Métodos de tratamiento de la esplenomegalia

Info

Publication number
CR20220374A
CR20220374A CR20220374A CR20220374A CR20220374A CR 20220374 A CR20220374 A CR 20220374A CR 20220374 A CR20220374 A CR 20220374A CR 20220374 A CR20220374 A CR 20220374A CR 20220374 A CR20220374 A CR 20220374A
Authority
CR
Costa Rica
Prior art keywords
methods
splenomegaly
treating
treating splenomegaly
therapeutic methods
Prior art date
Application number
CR20220374A
Other languages
English (en)
Inventor
Wayne Philip Rothbaum
Original Assignee
Telios Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Telios Pharma Inc filed Critical Telios Pharma Inc
Publication of CR20220374A publication Critical patent/CR20220374A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Processing Of Solid Wastes (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)

Abstract

Se describen métodos terapéuticos y composiciones farmacéuticas para tratar la esplenomegalia en un sujeto humano. En ciertas realizaciones, la invención incluye métodos terapéuticos para tratar la esplenomegalia usando un inhibidor de BTK.
CR20220374A 2020-01-08 2021-01-08 Métodos de tratamiento de la esplenomegalia CR20220374A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062958632P 2020-01-08 2020-01-08
PCT/US2021/012696 WO2021142257A1 (en) 2020-01-08 2021-01-08 Methods of treating splenomegaly

Publications (1)

Publication Number Publication Date
CR20220374A true CR20220374A (es) 2023-01-25

Family

ID=76788747

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20220374A CR20220374A (es) 2020-01-08 2021-01-08 Métodos de tratamiento de la esplenomegalia

Country Status (15)

Country Link
EP (2) EP3980069A4 (es)
JP (2) JP7771064B2 (es)
KR (1) KR20220130151A (es)
CN (1) CN114423457A (es)
AU (1) AU2021205484A1 (es)
BR (1) BR112022013646A2 (es)
CA (1) CA3164063A1 (es)
CO (1) CO2022010592A2 (es)
CR (1) CR20220374A (es)
IL (1) IL294582A (es)
JO (1) JOP20220168A1 (es)
MA (3) MA57226B1 (es)
MX (1) MX2022008490A (es)
TN (1) TN2022000185A1 (es)
WO (1) WO2021142257A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240024314A1 (en) 2020-01-08 2024-01-25 Telios Pharma, Inc. Methods of Treating Splenomegaly
TN2022000185A1 (en) * 2020-01-08 2024-04-01 Telios Pharma Inc Methods of treating splenomegaly
US20240293403A1 (en) * 2021-06-16 2024-09-05 Telios Pharma, Inc. Treatment of Symptoms Associated with Myeloproliferative Neoplasms
WO2023071973A1 (en) * 2021-10-26 2023-05-04 Shenzhen Targetrx, Inc. Fused bicyclic compound for inhibiting activity of tyrosine kinase
WO2024041614A1 (en) * 2022-08-25 2024-02-29 Beigene Switzerland Gmbh Solid forms comprising (s) -7- (1-acryloylpiperidin-4-yl) -2- (4-phenoxyphenyl) -4, 5, 6, 7-tetrahydropyrazolo [1, 5-a] pyrimidine-3-carboxamide, and oxalic acid, compositions and methods of use thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015057992A1 (en) * 2013-10-16 2015-04-23 Izumi Raquel Btk inhibitors for hematopoietic mobilization
WO2015081127A2 (en) * 2013-11-26 2015-06-04 Gilead Sciences, Inc. Therapies for treating myeloproliferative disorders
PL3179991T3 (pl) * 2014-08-11 2022-02-14 Acerta Pharma B.V. Kombinacje terapeutyczne inhibitora btk i inhibitora bcl-2
WO2016054491A1 (en) * 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
BR112020025881A2 (pt) * 2018-06-19 2021-03-23 Merck Patent Gmbh formas cristalinas de 1-(4-{[6-amino-5-(4-fenóxi-fenil)-pirimidin-4-ilamino]-metil}-4-fluoro-piperidin-1-il)-propenona, formas de sal do mesmo e processos para obter as mesmas
CN109942835A (zh) * 2019-03-27 2019-06-28 广州楹鼎生物科技有限公司 一种催化分解木质纤维原料的方法
TW202128156A (zh) * 2019-11-14 2021-08-01 美商夸格智財控股有限公司 用於癌症治療之btk抑制劑及mdm2抑制劑之組合
TN2022000185A1 (en) * 2020-01-08 2024-04-01 Telios Pharma Inc Methods of treating splenomegaly

Also Published As

Publication number Publication date
MA57226A1 (fr) 2023-02-28
JP2023509968A (ja) 2023-03-10
CO2022010592A2 (es) 2022-10-31
EP3980069A4 (en) 2022-08-17
MX2022008490A (es) 2022-10-13
CN114423457A (zh) 2022-04-29
MA57226B1 (fr) 2023-06-28
AU2021205484A1 (en) 2022-08-18
JOP20220168A1 (ar) 2023-01-30
KR20220130151A (ko) 2022-09-26
WO2021142257A1 (en) 2021-07-15
EP4000624A1 (en) 2022-05-25
CA3164063A1 (en) 2021-07-15
BR112022013646A2 (pt) 2022-10-04
JP7771064B2 (ja) 2025-11-17
TN2022000185A1 (en) 2024-04-01
IL294582A (en) 2022-09-01
MA69153A1 (fr) 2025-07-31
EP3980069A1 (en) 2022-04-13
JP2026027353A (ja) 2026-02-18
MA63848B1 (fr) 2024-10-31
MA63848A1 (fr) 2024-04-30

Similar Documents

Publication Publication Date Title
CR20220374A (es) Métodos de tratamiento de la esplenomegalia
SA522432691B1 (ar) المركبات الحلقية الماكروية وطرق العلاج المرتبطة بها
MX2022004983A (es) Composiciones de profarmaco y metodos de tratamiento.
MX2021004639A (es) Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para uso en el tratamiento de tumores solidos.
CO2023013050A2 (es) Composiciones de psilocibina, métodos para prepararlas y métodos de uso de estas
BR112022015416A2 (pt) Anticorpos anti-ror1 e composições
CO2020014599A2 (es) Métodos para tratar cáncer
CY1125104T1 (el) Συνθεσεις φλαγελλινης entrecoccus για χρηση στη θεραπεια
CY1124907T1 (el) Αναστολεις καλλικρεϊνης στο ανθρωπινο πλασμα
CY1124123T1 (el) Φαρμακευτικοι συνδυασμοι για θεραπεια καρκινου
EA202091112A1 (ru) Сокристаллы, фармацевтические композиции на их основе и способы лечения, предусматривающие их применение
MX2025003515A (es) Moduladores de akt1
CL2021000924A1 (es) Uso de reboxetina para el tratamiento de narcolepsia
CR20220280A (es) Terapia de combinación que comprende un inhibidor de alk2 y un inhibidor de jak2
BR112022011228A2 (pt) Formulação farmacêutica líquida, artigo de fabricação, kit e método para tratar uma doença ou distúrbio em um indivíduo
MX393452B (es) Tratamiento de los trastornos depresivos.
MX2025008092A (es) Inhibidores de kif18a y usos de los mismos
BR112021017550A2 (pt) Métodos de tratamento da amiloidose al
CO2023008676A2 (es) Compuestos polipéptidos modificados con lactama
MX2025008834A (es) Proteinas de fusion anti-pd-1/il-2, composiciones farmaceuticas y aplicaciones terapeuticas
MX2023015097A (es) Tratamiento de sintomas asociados a neoplasias mieloproliferativas.
MX2022005358A (es) Composiciones de copolímero de bloque sensibles al ph, micelas, y métodos de uso.
MX2021004396A (es) Metodos y composiciones para el tratamiento de la mucositis oral.
MX2021007330A (es) Composiciones y métodos terapéuticos para tratar cáncer usando ácido 6, 8-bis-benciltio-octanoico y un inhibidor de autofagia.
JOP20250311A1 (ar) مثبطات tyk2 وتركيبات وطرق لها